The DIS3L2 Knockout HeLa Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for functional analysis of the DIS3L2 gene. This loss-of-function model harnesses heterogeneous gene disruption across a pool of HeLa cells, minimizing clonal artifacts and enhancing the reproducibility of phenotypic studies. DIS3L2 encodes a 3??-5?? exoribonuclease that selectively degrades uridylated RNAs, positioning these cells as an essential tool for investigating RNA surveillance and decay mechanisms. The polyclonal format enables robust assessment of pathway perturbations without requiring single-cell cloning, making it suitable for high-throughput applications.
HeLa cells represent a human cervical carcinoma epithelial line immortalized through integration of HPV-18 DNA, characterized by extensive chromosomal abnormalities. This well-established model is a cornerstone of cancer research and general cell biology, offering rapid proliferation, easy genetic manipulation, and deep molecular characterization. The HeLa background provides a clinically relevant context for studying how DIS3L2 loss impacts RNA homeostasis in a malignant setting, where oncogenic signaling and aberrant RNA metabolism often intersect.
DIS3L2 functions within a tightly coordinated RNA decay network, where it specifically targets transcripts uridylated by terminal uridylyltransferases TUT4/ZCCHC11 and TUT7/ZCCHC6. Upstream, LIN28A and LIN28B recruit these enzymes to pre-let-7 miRNA, adding uridine tails that mark the precursor for DIS3L2-mediated degradation. This interaction directly controls let-7 maturation, thereby altering downstream gene expression programs involved in cell proliferation and differentiation. Beyond miRNA turnover, DIS3L2 also degrades uridylated mRNAs, linking it to broader mRNA quality control. Its activity is thus central to post-transcriptional gene regulation, with molecular partners TUT4/7 and LIN28 proteins forming a critical signaling axis.
In the context of HeLa cells, disrupting DIS3L2 creates a powerful system to model the consequences of impaired uridylated RNA decay. This knockout population is particularly significant for cancer biology, as DIS3L2 mutations are linked to Perlman syndrome, Wilms tumor, colorectal cancer, and multiple myeloma. The HeLa background, with its active cycling and HPV-driven oncogenic stress, allows researchers to explore how DIS3L2 deficiency influences tumor cell growth, apoptosis, and transcriptomic dynamics. By perturbing the LIN28-TUT4/7-DIS3L2 cascade, scientists can probe the molecular underpinnings of RNA dysregulation in disease.
This model supports a broad array of investigative techniques. Western blotting confirms DIS3L2 protein absence, while RT-qPCR and northern blotting quantify let-7 miRNA levels and uridylated RNA accumulation. RNA-seq reveals transcriptome-wide changes in RNA stability, and pulse-chase assays measure decay kinetics. Functional readouts such as cell proliferation and apoptosis assays dissect phenotypic outcomes. These cells are ideal for studying miRNA biogenesis, RNA decay mechanisms, and cancer-related RNA surveillance, as well as for drug target discovery in RNA degradation pathways. For further information, please contact Ascent Research.
